Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.

Lu G, Pine P, Leeds JM, DeGuzman F, Pratikhya P, Lin J, Malinowski J, Hollenbach SJ, Curnutte JT, Conley PB.

PLoS One. 2018 Mar 28;13(3):e0195122. doi: 10.1371/journal.pone.0195122. eCollection 2018.

2.

Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa.

Siegal D, Lu G, Leeds JM, Karbarz M, Castillo J, Mathur V, Hutchaleelaha A, Sinha U, Kitt M, McClure M, Hollenbach SJ, Curnutte JT, Conley PB, Crowther M.

Blood Adv. 2017 Sep 22;1(21):1827-1838. doi: 10.1182/bloodadvances.2017007112. eCollection 2017 Sep 26.

3.

Preclinical safety and efficacy of andexanet alfa in animal models.

Lu G, Hollenbach SJ, Baker DC, Tan S, Hutchaleelaha A, Curnutte JT, Conley PB.

J Thromb Haemost. 2017 Sep;15(9):1747-1756. doi: 10.1111/jth.13768. Epub 2017 Aug 5.

PMID:
28682477
4.

Effects of ibrutinib treatment on murine platelet function during inflammation and in primary hemostasis.

Lee RH, Piatt R, Conley PB, Bergmeier W.

Haematologica. 2017 Mar;102(3):e89-e92. doi: 10.3324/haematol.2016.155978. Epub 2016 Dec 15. No abstract available.

5.

The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, Parnell J, Smith LD, Davies A, Johnson PWM, Conley PB, Pandey A, Strefford JC, Stevenson FK, Packham G, Forconi F, Coffey GP, Burger JA, Steele AJ.

Clin Cancer Res. 2017 May 1;23(9):2313-2324. doi: 10.1158/1078-0432.CCR-16-1662. Epub 2016 Oct 3.

6.

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators.

N Engl J Med. 2016 Sep 22;375(12):1131-41. doi: 10.1056/NEJMoa1607887. Epub 2016 Aug 30.

7.

CalDAG-GEFI Deficiency Reduces Atherosclerotic Lesion Development in Mice.

Boulaftali Y, Owens AP 3rd, Beale A, Piatt R, Casari C, Lee RH, Conley PB, Paul DS, Mackman N, Bergmeier W.

Arterioscler Thromb Vasc Biol. 2016 May;36(5):792-9. doi: 10.1161/ATVBAHA.115.306347. Epub 2016 Mar 17.

8.

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA.

N Engl J Med. 2015 Dec 17;373(25):2413-24. doi: 10.1056/NEJMoa1510991. Epub 2015 Nov 11.

9.

Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor.

Cummings HE, Liu T, Feng C, Laidlaw TM, Conley PB, Kanaoka Y, Boyce JA.

J Immunol. 2013 Dec 15;191(12):5807-10. doi: 10.4049/jimmunol.1302187. Epub 2013 Nov 15.

10.

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.

Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U.

Nat Med. 2013 Apr;19(4):446-51. doi: 10.1038/nm.3102. Epub 2013 Mar 3.

PMID:
23455714
11.

The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.

Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN.

J Clin Invest. 2012 Oct;122(10):3579-92. doi: 10.1172/JCI38576. Epub 2012 Sep 17.

12.

Development of a perfusion chamber assay to study in real time the kinetics of thrombosis and the antithrombotic characteristics of antiplatelet drugs.

Stephens G, He M, Wong C, Jurek M, Luedemann HC, Shapurian G, Munnelly K, Muir C, Conley PB, Phillips DR, Andre P.

Thromb J. 2012 Aug 1;10(1):11. doi: 10.1186/1477-9560-10-11.

13.

Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.

Angiolillo DJ, Welsh RC, Trenk D, Neumann FJ, Conley PB, McClure MW, Stephens G, Kochman J, Jennings LK, Gurbel PA, Wójcik J, Dabrowski M, Saucedo JF, Stumpf J, Buerke M, Broderick S, Harrington RA, Rao SV.

Circ Cardiovasc Interv. 2012 Jun;5(3):347-56. doi: 10.1161/CIRCINTERVENTIONS.111.965608. Epub 2012 May 22.

14.

Rap1-Rac1 circuits potentiate platelet activation.

Stefanini L, Boulaftali Y, Ouellette TD, Holinstat M, Désiré L, Leblond B, Andre P, Conley PB, Bergmeier W.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):434-41. doi: 10.1161/ATVBAHA.111.239194. Epub 2011 Nov 10.

15.

A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.

Haberstock-Debic H, Andre P, Mills S, Phillips DR, Conley PB.

J Pharmacol Exp Ther. 2011 Oct;339(1):54-61. doi: 10.1124/jpet.111.184143. Epub 2011 Jul 5.

16.

Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding.

André P, DeGuzman F, Haberstock-Debic H, Mills S, Pak Y, Inagaki M, Pandey A, Hollenbach S, Phillips DR, Conley PB.

J Pharmacol Exp Ther. 2011 Jul;338(1):22-30. doi: 10.1124/jpet.110.178574. Epub 2011 Mar 29.

17.

Role of the P2Y12 receptor in the modulation of murine dendritic cell function by ADP.

Ben Addi A, Cammarata D, Conley PB, Boeynaems JM, Robaye B.

J Immunol. 2010 Nov 15;185(10):5900-6. doi: 10.4049/jimmunol.0901799. Epub 2010 Oct 15.

18.

Autocrine purinergic receptor signaling is essential for macrophage chemotaxis.

Kronlage M, Song J, Sorokin L, Isfort K, Schwerdtle T, Leipziger J, Robaye B, Conley PB, Kim HC, Sargin S, Schön P, Schwab A, Hanley PJ.

Sci Signal. 2010 Jul 27;3(132):ra55. doi: 10.1126/scisignal.2000588.

19.

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.

Gurbel PA, Bliden KP, Antonino MJ, Stephens G, Gretler DD, Jurek MM, Pakyz RE, Shuldiner AR, Conley PB, Tantry US.

J Thromb Haemost. 2010 Jan;8(1):43-53. doi: 10.1111/j.1538-7836.2009.03648.x. Epub 2009 Oct 11.

20.

G-protein-coupled receptors as signaling targets for antiplatelet therapy.

Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, Moliterno DJ, French PA, Steinhubl SR, Becker RC; 2008 Platelet Colloquium Participants.

Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):449-57. doi: 10.1161/ATVBAHA.108.176388. Epub 2008 Nov 20. Review.

21.

Distinct clathrin-coated pits sort different G protein-coupled receptor cargo.

Mundell SJ, Luo J, Benovic JL, Conley PB, Poole AW.

Traffic. 2006 Oct;7(10):1420-31. Epub 2006 Aug 10.

22.

Distinct roles for protein kinase C isoforms in regulating platelet purinergic receptor function.

Mundell SJ, Jones ML, Hardy AR, Barton JF, Beaucourt SM, Conley PB, Poole AW.

Mol Pharmacol. 2006 Sep;70(3):1132-42. Epub 2006 Jun 27.

23.

Therapeutic approaches in arterial thrombosis.

Phillips DR, Conley PB, Sinha U, Andre P.

J Thromb Haemost. 2005 Aug;3(8):1577-89. Review.

24.

Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling.

Nanda N, Andre P, Bao M, Clauser K, Deguzman F, Howie D, Conley PB, Terhorst C, Phillips DR.

Blood. 2005 Nov 1;106(9):3028-34. Epub 2005 Jul 21.

25.

Agonist-induced calcium response in single human platelets assayed in a microfluidic device.

Tran L, Farinas J, Ruslim-Litrus L, Conley PB, Muir C, Munnelly K, Sedlock DM, Cherbavaz DB.

Anal Biochem. 2005 Jun 15;341(2):361-8.

PMID:
15907883
26.

Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation.

Nanda N, Bao M, Lin H, Clauser K, Komuves L, Quertermous T, Conley PB, Phillips DR, Hart MJ.

J Biol Chem. 2005 Jul 1;280(26):24680-9. Epub 2005 Apr 25.

27.

P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms.

Hardy AR, Conley PB, Luo J, Benovic JL, Poole AW, Mundell SJ.

Blood. 2005 May 1;105(9):3552-60. Epub 2005 Jan 21.

28.

Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.

André P, LaRocca T, Delaney SM, Lin PH, Vincent D, Sinha U, Conley PB, Phillips DR.

Circulation. 2003 Nov 25;108(21):2697-703. Epub 2003 Nov 3.

29.

Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis.

Conley PB, Delaney SM.

Curr Opin Hematol. 2003 Sep;10(5):333-8. Review.

PMID:
12913786
30.

P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries.

Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, Koller B, Phillips DR, Conley PB.

J Clin Invest. 2003 Aug;112(3):398-406.

31.

Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding.

Cattaneo M, Zighetti ML, Lombardi R, Martinez C, Lecchi A, Conley PB, Ware J, Ruggeri ZM.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1978-83. Epub 2003 Feb 10.

32.

Immunolocalization of P2Y1 and TPalpha receptors in platelets showed a major pool associated with the membranes of alpha -granules and the open canalicular system.

Nurden P, Poujol C, Winckler J, Combrié R, Pousseau N, Conley PB, Levy-Toledano S, Habib A, Nurden AT.

Blood. 2003 Feb 15;101(4):1400-8. Epub 2002 Oct 10.

33.

Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets.

Larson MK, Chen H, Kahn ML, Taylor AM, Fabre JE, Mortensen RM, Conley PB, Parise LV.

Blood. 2003 Feb 15;101(4):1409-15. Epub 2002 Oct 17.

34.

Impaired activation of murine platelets lacking G alpha(i2).

Jantzen HM, Milstone DS, Gousset L, Conley PB, Mortensen RM.

J Clin Invest. 2001 Aug;108(3):477-83.

35.

Novel tricyclic benzothiazolo[2,3-c]thiadiazine antagonists of the platelet ADP receptor (P2Y(12)).

Scarborough RM, Laibelman AM, Clizbe LA, Fretto LJ, Conley PB, Reynolds EE, Sedlock DM, Jantzen H.

Bioorg Med Chem Lett. 2001 Jul 23;11(14):1805-8.

PMID:
11459636
36.

Identification of the platelet ADP receptor targeted by antithrombotic drugs.

Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB.

Nature. 2001 Jan 11;409(6817):202-7.

PMID:
11196645
37.

Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation.

Jantzen HM, Gousset L, Bhaskar V, Vincent D, Tai A, Reynolds EE, Conley PB.

Thromb Haemost. 1999 Jan;81(1):111-7.

PMID:
10348701
38.

Expression of alpha IIb beta 3 integrin (GPIIb-IIIa) in myeloid cell lines and normal CD34+/CD33+ bone marrow cells.

Wall CD, Conley PB, Armendariz-Borunda J, Sudarshan C, Wagner JE, Raghow R, Jennings LK.

Blood Cells Mol Dis. 1997 Dec;23(3):361-76.

PMID:
9398537
39.
40.

A transcriptional hierarchy involved in mammalian cell-type specification.

Kuo CJ, Conley PB, Chen L, Sladek FM, Darnell JE Jr, Crabtree GR.

Nature. 1992 Jan 30;355(6359):457-61.

PMID:
1734282
41.

Characterization of a cofactor that regulates dimerization of a mammalian homeodomain protein.

Mendel DB, Khavari PA, Conley PB, Graves MK, Hansen LP, Admon A, Crabtree GR.

Science. 1991 Dec 20;254(5039):1762-7.

PMID:
1763325
42.
43.

Molecular cloning, functional expression, and chromosomal localization of mouse hepatocyte nuclear factor 1.

Kuo CJ, Conley PB, Hsieh CL, Francke U, Crabtree GR.

Proc Natl Acad Sci U S A. 1990 Dec;87(24):9838-42.

44.

HNF-1 shares three sequence motifs with the POU domain proteins and is identical to LF-B1 and APF.

Baumhueter S, Mendel DB, Conley PB, Kuo CJ, Turk C, Graves MK, Edwards CA, Courtois G, Crabtree GR.

Genes Dev. 1990 Mar;4(3):372-9.

45.
46.

Characterization of phycobiliprotein and linker polypeptide genes in Fremyella diplosiphon and their regulated expression during complementary chromatic adaptation.

Grossman AR, Lemaux PG, Conley PB, Bruns BU, Anderson LK.

Photosynth Res. 1988 Jul;17(1-2):23-56. doi: 10.1007/BF00047680.

PMID:
24429660
47.

Molecular characterization and evolution of sequences encoding light-harvesting components in the chromatically adapting cyanobacterium Fremyella diplosiphon.

Conley PB, Lemaux PG, Grossman A.

J Mol Biol. 1988 Feb 5;199(3):447-65. Erratum in: J Mol Biol 1988 Oct 5;203(3):835.

PMID:
3127591
48.
49.

Regulated synthesis of phycobilisome components.

Grossman AR, Lemaux PG, Conley PB.

Photochem Photobiol. 1986 Dec;44(6):827-37. Review. No abstract available.

PMID:
3104939
50.

Genes encoding major light-harvesting polypeptides are clustered on the genome of the cyanobacterium Fremyella diplosiphon.

Conley PB, Lemaux PG, Lomax TL, Grossman AR.

Proc Natl Acad Sci U S A. 1986 Jun;83(11):3924-8.

Supplemental Content

Loading ...
Support Center